ObjectiveTo describe the long term outcomes, treatment pathways and risk factors for patients diagnosed with Hypoplastic Left Heart Syndrome (HLHS) in England and Wales.
MethodsThe UKs national audit database captures every procedure undertaken for congenital heart disease and updated life status for patients resident in England and Wales. HLHS patients born between 2000 and 2015 were identified using codes from the International Paediatric and Congenital Cardiac Code.
ResultsThere were 976 patients with HLHS. Of these, 9.6% had a pre-pathway intervention, 89.5% underwent a traditional pathway of staged palliation and 6.4% of infants underwent a hybrid pathway. Patients undergoing pre-pathway procedures or the hybrid pathway were more complex, exhibiting higher rates of prematurity and acquired comorbidity. Pre-pathway intervention was associated with the highest in-hospital mortality (34.0%).44.6% of patients had an off pathway procedure after their primary procedure, most frequently stenting or dilation of residual or re-coarctation and most commonly occurring between Stage 1 and 2.The survival rate at 1 year and 5 years was 60.7% (95% CI 57.5-63.7) and 56.3% (53.0-59.5) respectively. Patients with an antenatal diagnosis (multivariable hazard ratio (MHR) 1.63 (95% CI 1.12-2.38)), low weight (<2.5kg) (MHR 1.49 (1.05-2.11)) or the presence of an acquired comorbidity ) were less likely to survive.
ConclusionTreatment pathways amongst HLHS patients are complex and variable. It is essential that the long term outcomes of conditions like HLHS that require serial interventions are studied to provide a fuller picture and to inform quality assurance and improvement.
3
KEY MESSAGES